Floatz logo

(+)-VINCRISTINE

Fallopian Tube Carcinosarcoma

National Cancer Institute (NCI)Small moleculePhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
81/ 100

Competitive context

14 Active assets in the Fallopian Tube Carcinosarcoma cohort.

Asset / SponsorPhaseRating
Irinotecan
National Cancer Institute (NCI)
Phase 2B
Cyclophosphamide
Mayo Clinic
Phase 2B
Inno-206
National Cancer Institute (NCI)
Phase 2B
Pembrolizumab
Mayo Clinic
Phase 2B
Epirubicin
Mayo Clinic
Phase 2B

View all 23 →

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →